ATC Group: B02BD Blood coagulation factors

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of B02BD in the ATC hierarchy

Level Code Title
1 B Blood and blood forming organs
2 B02 Antihemorrhagics
3 B02B Vitamin K and other hemostatics
4 B02BD Blood coagulation factors

Group B02BD contents

Code Title
B02BD01 Coagulation factor IX, II, VII and X in combination
B02BD02 Coagulation factor VIII
B02BD03 Factor VIII inhibitor bypassing activity
B02BD04 Coagulation factor IX
B02BD05 Coagulation factor VII
B02BD06 Von Willebrand factor and coagulation factor VIII in combination
B02BD07 Coagulation factor XIII
B02BD08 Eptacog alfa (activated)
B02BD10 Von Willebrand factor
B02BD11 Catridecacog
B02BD13
B02BD14
B02BD15
B02BD16
B02BD30 Thrombin

Active ingredients in B02BD

Active Ingredient Description
Catridecacog
Coagulation factor IX

Factor IX is a single chain glycoprotein with a molecular mass of about 68,000 Dalton. It is a vitamin-K dependent coagulation factor and it is synthesised in the liver. Factor IX is activated by factor XIa in the intrinsic coagulation pathway and by the factor VII/tissue factor complex in the extrinsic pathway. Activated factor IX, in combination with activated factor VIII, activates factor X.

Coagulation factor IX complex
Coagulation factor VII
Coagulation factor VIIa

Pharmacological doses of rFVIIa activate factor X directly on the surface of activated platelets, localized to the site of injury, independently of tissue factor. This results in the conversion of prothrombin into large amounts of thrombin independently of tissue factor.

Coagulation factor VIII

Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X (factor Xa). Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.

Factor VIII inhibitor bypass activity
Coagulation factor X

Coagulation factor X is derived from human plasma and used as a replacement for the naturally existing coagulation factor X in patients with hereditary factor X deficiency.

Coagulation factor XIII

Factor XIII connects the amino group of lysine with glutamine via its enzymatic function (transamidase activity), thereby leading to the cross-linking of fibrin molecules. This is the final stage of blood coagulation. Fibrin cross-linking and stabilisation promote the penetration of fibroblasts and support wound healing.

Eftrenonacog alfa

Eftrenonacog alfa is a long-acting, fully recombinant, fusion protein comprising human coagulation factor IX covalently linked to the Fc domain of human immunoglobulin G1, and produced by recombinant DNA technology. Haemophilia B is an X-linked hereditary disorder of blood coagulation due to decreased levels of factor IX and results in bleeding into joints, muscles or internal organs, either spontaneously or as a result of accidental or surgical trauma. By replacement therapy the plasma level of factor IX is increased thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.

Etranacogene dezaparvovec

Etranacogene dezaparvovec is a gene therapy product designed to introduce a copy of the human Factor IX coding DNA sequence into hepatocytes to address the root cause of the Haemophilia B disease. Etranacogene dezaparvovec partially or completely ameliorates the deficiency of circulating Factor IX procoagulant activity in patients with Haemophilia B.

Lonoctocog alfa

Lonoctocog alfa is a recombinant human protein that replaces the missing coagulation factor VIII needed for effective hemostasis. Lonoctocog alfa is a single polypeptide chain with a truncated B-domain that allows for a covalent bridge to link the factor VIII heavy and light chains. Lonoctocog alfa has demonstrated a higher VWF affinity relative to full-length rFVIII. VWF stabilizes factor VIII and protects it from degradation. Activated lonoctocog alfa has an amino acid sequence identical to endogenous FVIIIa.

Moroctocog alfa

Moroctocog alfa is a B-domain deleted recombinant coagulation factor VIII. Moroctocog alfa has functional characteristics comparable to those of endogenous factor VIII. Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C. By replacement therapy, the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.

Nonacog alfa

Nonacog alfa is a recombinant coagulation factor IX. Recombinant coagulation factor IX is a recombinant DNA-based protein therapeutic which has structural and functional characteristics comparable to endogenous factor IX. Haemophilia B is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor IX. By replacement therapy the plasma levels of factor IX is increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.

Octocog alfa

Octocog alfa (Full length recombinant human coagulation factor VIII (rDNA)) is a purified protein that has 2,332 amino acids. It is produced by recombinant DNA technology in baby hamster kidney cells (BHK) into which the human factor VIII gene has been introduced.

Protein S
Rurioctocog alfa pegol

Rurioctocog alfa pegol, is a pegylated recombinant human factor VIII with an extended half-life. Rurioctocog alfa pegol is a covalent conjugate of octocog alfa consisting of 2,332 amino acids with polyethylene glycol (PEG) reagent (MW 20 kDa). The therapeutic activity of rurioctocog alfa pegol is derived from octocog alfa, which is produced by recombinant DNA technology from a Chinese hamster ovary cell line. Octocog alfa is then covalently conjugated with the PEG reagent. The PEG moiety is conjugated to octocog alfa to increase the plasma half-life.

Susoctocog alfa

Susoctocog alfa is a recombinant, B-domain deleted, porcine sequence Factor VIII. It is a glycoprotein. Acquired haemophilia is a rare bleeding disorder in which patients with normal Factor VIII genes develop inhibitory autoantibodies directed against Factor VIII. These autoantibodies neutralize circulating human Factor VIII thus creating a deficiency of available Factor VIII. Susoctocog alfa temporarily replaces the inhibited endogenous Factor VIII that is needed for effective haemostasis.

Thrombin
Valoctocogene roxaparvovec

Valoctocogene roxaparvovec is an adeno-associated virus serotype 5 (AAV5) based gene therapy vector causing the expression of the B-domain deleted SQ form of a recombinant human factor VIII (hFVIII-SQ) under the control of a liver-specific promoter. The expressed hFVIII-SQ replaces the missing coagulation factor VIII needed for effective haemostasis.

Von Willebrand factor

Administration of von Willebrand factor allows correction of the haemostatic abnormalities exhibited by patients who suffer from von Willebrand factor deficiency.

Related product monographs

Title Information Source Document Type  
ADYNOVATE Powder for injection Health Products Regulatory Authority (ZA) MPI, Generic
ADYNOVI Powder and solvent for solution for injection European Medicines Agency (EU) MPI, EU: SmPC
AFSTYLA Powder and solvent for solution for injection European Medicines Agency (EU) MPI, EU: SmPC
ALPROLIX Powder and solvent for solution for injection European Medicines Agency (EU) MPI, EU: SmPC
BENEFIX Powder and solvent for solution for injection European Medicines Agency (EU) MPI, EU: SmPC
BERIATE Powder and solvent for solution for injection / infusion Medicines Authority (MT) MPI, EU: SmPC
CEVENFACTA Powder and solvent for solution for injection European Medicines Agency (EU) MPI, EU: SmPC
COAGADEX Powder and solvent for solution for injection European Medicines Agency (EU) MPI, EU: SmPC
ELOCTATE Powder for solution, lyophilized Health Products and Food Branch (CA) MPI, CA: SPM
EMOCLOT Powder and solvent for solution for infusion Medicines Authority (MT) MPI, EU: SmPC
FEIBA Powder and solvent for solution for infusion Health Products Regulatory Authority (IE) MPI, EU: SmPC
FIBROGAMMIN Powder and solvent for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
HAEMOCTIN Powder and solvent for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
HAEMONINE Powder and solvent for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
HEMOFIL M Solution for infusion FDA, National Drug Code (US) MPI, US: SPL/Old
KCENTRA Powder for solution for infusion, lyophilized FDA, National Drug Code (US) MPI, US: SPL/PLR
KOATE-DVI Powder fo solution Health Sciences Authority (SG) MPI, Generic
KOVALTRY Powder and solvent for solution for injection European Medicines Agency (EU) MPI, EU: SmPC
NOVOSEVEN Powder and solvent for solution for injection European Medicines Agency (EU) MPI, EU: SmPC
NUWIQ Powder for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
OBIZUR Powder and solvent for solution for injection European Medicines Agency (EU) MPI, EU: SmPC
OCTANINE Powder for solution for injection Medicines Authority (MT) MPI, EU: SmPC
OPTIVATE Powder and solvent for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
REFACTO AF Powder and solvent for solution for injection European Medicines Agency (EU) MPI, EU: SmPC
VEYVONDI Powder and solvent for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
VIHUMA Powder and solvent for solution for injection European Medicines Agency (EU) MPI, EU: SmPC
VONCENTO Powder and solvent for solution for injection/infusion European Medicines Agency (EU) MPI, EU: SmPC
WILATE Powder and solvent for solution for injection Health Products Regulatory Authority (IE) MPI, EU: SmPC
WILLFACT Powder and solvent for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
ZONOVATE Powder for solution, lyophilized Health Products and Food Branch (CA) MPI, CA: SPM